Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05580445
Other study ID # CT-707-1
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date August 11, 2022
Est. completion date August 11, 2024

Study information

Verified date November 2023
Source Shouyao Holdings (Beijing) Co. LTD
Contact Yinghui Sun, PhD
Phone 86-10-88858616
Email yhsun@centaurusbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the safety, tolerability, pharmacokinetics and antineoplastic activity of CT-707 in combination with toripalimab and gemcitabine in patients with advanced pancreatic cancer


Description:

This is a phase Ib/II, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics and antineoplastic activity of CT-707 in combination with toripalimab and gemcitabine in patients with advanced pancreatic cancer.The study consists of two parts, dose-escalation part and dose-expansion part. Both parts will enroll patients with advanced pancreatic cancer. Dose-escalation study is designed to determine the dose-limiting toxicity (DLTs) and recommended phase II dose (RP2D), and to characterize the safety, tolerability, and pharmacokinetics (PK) profile of CT-707 in combination with toripalimab and gemcitabine. Dose-expansion study phase is designed to evaluate the antitumor activity (objective response rate, progression-free survival, overall survival) of CT-707 in combination with toripalimab and gemcitabine in patients with advanced pancreatic cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 114
Est. completion date August 11, 2024
Est. primary completion date August 11, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - For inclusion in this study, patients must fulfil the following criteria: 1. Male or female (age of 18~75 years old). 2. Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 3. Patients must have a life expectancy of = 3 months. 4. Patients must have histologically or cytologically confirmed advanced pancreatic adenocarcinoma or poorly differentiated pancreatic carcinoma that is metastatic to distant sites. 5. Patients are required to have measurable disease (RECIST v1.1), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan. 6. Patients must have adequate organ and marrow function as defined below: Blood routine: Absolute neutrophil count (ANC) = 1.5×10^9/L; Platelet count (PLT) = 100×10^9/L; Hemoglobin (HGB) = 90 g/L. Liver function: Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) = 2.5 times upper limit of normal (ULN), total bilirubin (TBIL) = 1.5 times ULN in patients without liver metastases; AST and ALT = 5 times ULN, TBIL =3 times ULN in patients with liver metastases. Renal function: Serum creatinine (Scr) =1.5 times ULN or creatinine clearance =60 mL/min/1.73 m2. Coagulation function: Activated partial thromboplastin time (APTT) = 1.5 times ULN; International Normalized ratio (INR) = 1.5 times ULN. 7. Patients must have recovered from any acute adverse events (except alopecia and peripheral neurotoxicity = Grade 2). 8. Patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months after the trial; female participants must have a negative serum pregnancy test within 7 days prior to treatment. Exclusion Criteria: - Patients must not enroll in this study if any of the following exclusion criteria are fulfilled: 1. Patients who have received chemotherapy, biotherapy, endocrine therapy, immunotherapy and other anti-tumor therapy within 4 weeks prior to the first use of the study drug. 2. Patients who have received clinical investigational drug or treatment within 4 weeks prior to the first use of the study drug. 3. Patients who have received major surgery within 4 weeks or had minor surgery within 2 weeks before the first dose of administration. 4. Patients who have previously received FAK inhibitor or programmed cell death protein 1/programmed cell death ligand 1 (PD-1/L1) antibody and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody are not eligible. 5. Patients receiving any medications or substances that are known to be moderate to strong inhibitors or inducers of CYP3A4 and which cannot be discontinued at least 1 week prior to the first dose of administration . 6. Patients who have active central nervous system (CNS)or leptomeningeal metastasis. However, participants who are asymptomatic, clinically stable, and did not require steroid therapy at least 4 weeks before the first dose of study treatment are eligible. 7. Patients who have cardiovascular and cerebrovascular diseases currently or within the last 6 months, including but not limited to: I. Myocardial infarction; II. Unstable Angina pectoris; III. Cerebrovascular accident; IV. Other acute uncontrolled heart disease; Mean resting corrected QTc interval using the Fridericia formula (QTcF) > 470 msec/female and > 450 msec/male; Severe arrhythmias or abnormal cardiac conduction, such as ventricular arrhythmias requiring clinical intervention, degree ii-iii atrioventricular block, etc; Various factors that may increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, a family history of a first-degree relative with long QT syndrome or sudden unexplained death before the age of 40, receiving any medication with known QT prolongation; Left ventricular ejection fraction (LVEF) < 40 % within 4 weeks prior to the first use of the study drug; Hypertension remains uncontrolled after aggressive antihypertensive therapy. Uncontrolled hypertension was defined as systolic blood pressure > 185 mmHg and/or diastolic blood pressure > 110 mmHg measured on 3 repetitions at least 10 minutes apart. 8. Patients suffering from conditions which are likely to adversely affect gastrointestinal motility (ulcerative disease, uncontrollable nausea, vomiting, diarrhea, or poor absorption syndrome). 9. Any evidence of severe or uncontrolled systemic disease, active infection or active bleeding diatheses, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV). 10. Patients have uncontrolled pleural, pericardial or abdominal effusion requiring drainage excluding those staying stable for at least two weeks after drainage. 11. Patients have active autoimmune disease that requires systemic treatment (immunomodulatory drugs, corticosteroids, or immunomodulatory drugs) in the past 2 years. 12. Patients with severely impaired lung functions such as pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia and drug-associated pneumonia. 13. Patients have allergic reactions to any component of CT-707, toripalimab and gemcitabine, or with history of severe allergic reactions to other monoclonal antibodies or gemcitabine. 14. Female patients who are pregnant or breast-feeding, or male or female patients of reproductive potential who are not employing an effective method of birth control. 15. Patients with mental disorder, alcohol and/or drug dependence. 16. The investigator considers that the subject has a history of serious systemic diseases or other reasons and is not suitable or not willing to participate in this clinical study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CT-707
Focal Adhesion Kinase (FAK) inhibitor
Toripalimab
Programmed Death 1(PD-1) antibody
Gemcitabine
nucleoside inhibitor

Locations

Country Name City State
China Fudan University Shanghai Cancer Center Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shouyao Holdings (Beijing) Co. LTD

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Predictive biomarkers for response to the combination of CT-707, toripalimab and gemcitabine To assess putative predictive biomarkers such as PD-L1 and p-FAK Up to 24 months
Primary Recommended phase 2 dose (RP2D) of CT-707 in combination with toripalimab and gemcitabine The RP2D will be determined from the maximum tolerated dose (MTD) found in the dose-escalation cohort. The MTD is determined as the dose at which no more than one patient (out of six) experiences any drug-related toxicity (DLT) Up to 24 months
Secondary Incidence of adverse events (AEs) and serious adverse events (SAEs) Characterization of the safety and tolerability as determined by changes in laboratory values and electrocardiograms Up to 24 months
Secondary Pharmacokinetics (Cmax) for CT-707 Defined as maximum observed plasma concentration Cycle 1 (each cycle is 21 days)
Secondary Pharmacokinetics (Tmax) for CT-707 Defined as time to maximum plasma concentration Cycle 1 (each cycle is 21 days)
Secondary Pharmacokinetics (AUC0-t) for CT-707 Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration Cycle 1 (each cycle is 21 days)
Secondary Pharmacokinetics (t½) for CT-707 Defined as the apparent plasma terminal phase disposition half-life Cycle 1 (each cycle is 21 days)
Secondary Overall response rate (ORR) as assessed by RECIST 1.1 criteria Preliminary measure of anti-tumor activity of CT-707 in combination with toripalimab and gemcitabine Up to 24 months
Secondary Progression free survival (PFS) according to RECIST v1.1 criteria Preliminary measure of anti-tumor activity of CT-707 in combination with toripalimab and gemcitabine Up to 24 months
Secondary Disease control rate (DCR) according to RECIST v1.1 Preliminary measure of anti-tumor activity of CT-707 in combination with toripalimab and gemcitabine Up to 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Not yet recruiting NCT03662035 - Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer Phase 2
Recruiting NCT05085548 - ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies Phase 1
Recruiting NCT06111274 - A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT04137536 - A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer Phase 1
Completed NCT04617067 - Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT04469556 - Pancreatic Adenocarcinoma Signature Stratification for Treatment Phase 2
Recruiting NCT04104672 - A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies Phase 1
Not yet recruiting NCT05100329 - A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer Phase 2
Completed NCT02101580 - Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer Phase 1
Not yet recruiting NCT06329947 - A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD Phase 2
Recruiting NCT02135822 - Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer Phase 2
Recruiting NCT04803851 - Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT03415802 - Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer Phase 2
Recruiting NCT05162118 - Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04643405 - APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma Phase 1/Phase 2
Recruiting NCT03889795 - Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors Phase 1
Completed NCT01303172 - A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT06422156 - SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT04931381 - Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer Phase 3